Jeff Yass’s Orchestra BioMed OBIO Stock Holding History

Jeff Yass’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$284K	Sell	65,804 -31,717	-33%	-$130K	﹤0.01%	11172
2026 Q1	$414K	Sell	97,521 -57,609	-37%	-$245K	﹤0.01%	10128
2025 Q4	$644K	Buy	155,130 +57,025	+58%	+$230K	﹤0.01%	8220
2025 Q3	$243K	Sell	98,105 -20,453	-17%	-$56.4K	﹤0.01%	10576
2025 Q2	$318K	Buy	118,558 +85,570	+259%	+$250K	﹤0.01%	10205
2025 Q1	$141K	Buy	32,988 +20,819	+171%	+$104K	﹤0.01%	11278
2024 Q4	$48.7K	Buy	+12,169	New	+$65.4K	﹤0.01%	11689
2023 Q4	–	Sell	-12,647	Closed	-$110K	–	13019
2023 Q3	$110K	Buy	+12,647	New	+$85K	﹤0.01%	10839

Other funds holding OBIO

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Jeff Yass's OBIO Position: Q2 2026 in Review

Jeff Yass reduced its Orchestra BioMed (OBIO) stake by 33% in Q2 2026, selling an estimated $130K and leaving 65,804 shares worth $284K. The position accounts for ﹤0.01% of the portfolio, ranked #11172.

Jeff Yass first reported a position in OBIO in Q3 2023 and has held it in 8 quarters since. The position peaked at $644K in Q4 2025. 76 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

Jeff Yass held 65,804 shares of Orchestra BioMed worth $284K as of Q2 2026.
Jeff Yass sold 31,717 Orchestra BioMed shares in Q2 2026, an estimated $130K.
Orchestra BioMed made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #11172 holding.
Jeff Yass first reported a position in Orchestra BioMed in Q3 2023 and has held it in 8 quarters since.
Jeff Yass's Orchestra BioMed position peaked at $644K in Q4 2025.
76 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.